Wagner Klaus W. 4

Accession 0000950170-24-099299

CIK 0001782303other

View on SEC.gov Company Profile

Filed

Aug 19, 8:00 PM ET

Accepted

Aug 20, 7:06 PM ET

Size

25.3 KB

Accession

0000950170-24-099299

Insider Transaction Report

Form 4

Period: 2024-08-19

Boundless Bio, Inc.BOLD

Wagner Klaus W.

Chief Medical Officer

Transactions

Disposition to Issuer
Stock Option
2024-08-19−68,080→ 0 total
Exercise: $8.19Exp: 2034-02-14→ Common Stock (68,080 underlying)
Award
Stock Option
2024-08-19+68,080→ 68,080 total
Exercise: $3.56Exp: 2034-02-14→ Common Stock (68,080 underlying)
Award
Stock Option
2024-08-19+102,564→ 102,564 total
Exercise: $3.56Exp: 2032-02-23→ Common Stock (102,564 underlying)
Disposition to Issuer
Stock Option
2024-08-19−102,564→ 0 total
Exercise: $4.10Exp: 2032-02-23→ Common Stock (102,564 underlying)
Disposition to Issuer
Stock Option
2024-08-19−9,635→ 0 total
Exercise: $4.10Exp: 2032-12-12→ Common Stock (9,635 underlying)
Disposition to Issuer
Stock Option
2024-08-19−94,871→ 0 total
Exercise: $4.10Exp: 2033-06-12→ Common Stock (94,871 underlying)
Disposition to Issuer
Stock Option
2024-08-19−41,745→ 0 total
Exercise: $16.00Exp: 2034-03-26→ Common Stock (41,745 underlying)
Award
Stock Option
2024-08-19+9,635→ 9,635 total
Exercise: $3.56Exp: 2032-12-12→ Common Stock (9,635 underlying)
Award
Stock Option
2024-08-19+94,871→ 94,871 total
Exercise: $3.56Exp: 2033-06-12→ Common Stock (94,871 underlying)
Award
Stock Option
2024-08-19+41,745→ 41,745 total
Exercise: $3.56Exp: 2034-03-26→ Common Stock (41,745 underlying)

Footnotes (7)

[F1]The stock option vested as to 25% of the underlying shares on February 22, 2023, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter.
[F2]On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged.
[F3]The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023.
[F4]The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023.
[F5]The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024.
[F6]The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024.
[F7]The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Boundless Bio, Inc.

CIK 0001782303

→

Entity typeother

Related Parties

filerCIK 0001766477

Filing Metadata

Form type: 4
Filed: Aug 19, 8:00 PM ET
Accepted: Aug 20, 7:06 PM ET
Size: 25.3 KB

View on SEC.gov